Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs.

Roche presented early-stage data on its obesity injection and pill at EASD. Meanwhile, Oura enters into metabolic health ...

Novartis says it's not interested in joining weight-loss drugs frenzy. CEO Vas Narasimhan explained why today on CNBC's "Squawk Box Europe".

The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders Novo Nordisk ( NVO) and Eli Lilly ( LLY) by introducing GLP-1 pills.

Jim Cramer warned that if the housing market rally keeps going, it might lead to a sell-off if the Federal Reserve announces ...

Most trillion-dollar companies today are in the technology sector, but one particular healthcare stock is knocking on the ...

Jared Holz thought about taking one of the new GLP-1 drugs for weight loss for months before he actually filled the ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

Noom is best known for its eponymous app that helps people become healthier and lose weight by making changes to their diet ...

The bold move has been accompanied by a full-page ad in the Wall Street Journal explaining its reasoning, and claiming that ...

Rhythm Pharmaceuticals (RYTM) stock gains as JMP Securities issues a positive view on the company citing its lead product ...

In an unconventional alliance, North Carolina State Treasurer Dale Folwell, a Republican, spoke on Capitol Hill at a ...